Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

AMP Health vs Basal Health

AMP Health
Graded #200

Higher grade

vs+18.39999999999999
Basal Health
Graded #494

Lower grade

The verdict

AMP Health takes it — 66.1/100 to 47.7/100.

AMP Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. AMP Health offers compounded semaglutide (injectable and oral) from $199/mo and tirzepatide from $309/mo, plus a $79/mo subscription fee.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueAMP Health +15
60
45
Dose & formulationAMP Health +48
88
40
Clinical oversightAMP Health +27
75
48
Labs & monitoringAMP Health +2
52
50
FulfillmentAMP Health +4
62
58
Contract termsBasal Health +14
41
55
AMP Health · left barBasal Health · right bar

The numbers

MetricAMP HealthBasal Health
WeighScore66.1/10047.7/100
GradeCC
Scorecard rank#200#494
Semaglutide$199/mo (compounded)Not disclosed
Tirzepatide$309/mo (compounded)Not disclosed
CoverageCoverage not publishedAll 50 states
Brand-name accessYesCompounded only
Oral / sublingualYesInjection only
AMP Health

Graded #200 · C

Strengths

  • Semaglutide in both injectable and oral formats
  • Tirzepatide available
  • 30-day satisfaction guarantee
  • Personal nutrition plan and health coaching included

Where it loses points

  • $79/mo subscription fee on top of medication ($278–$388/mo total)
  • No visible LegitScript or PCAB accreditation
  • No physical address disclosed
  • States served not disclosed
  • Brand Wegovy listed but out of stock
Basal Health

Graded #494 · C

Strengths

  • Stated nationwide coverage (50 states + DC)
  • Metabolic-framework positioning rather than single-product
  • Clinician-supervised dosing rather than a fixed protocol
  • Adaptive monitoring approach

Where it loses points

  • No pricing shown publicly — you must complete intake to see cost
  • Compounding pharmacy partner not named
  • GLP-1 molecules not specified (semaglutide vs tirzepatide vs oral)
  • No LegitScript badge visible on the homepage
  • No FDA compounded-medication disclaimer on the pages reviewed

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard